Cimzia's setback paves way for other TNF inhibitors in Crohn's disease.
Sheridan
Cormac
C
D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy*; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol